These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17030738)

  • 21. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
    Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
    Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).
    Stocchi F; Marconi S
    Clin Neuropharmacol; 2010 Jul; 33(4):198-203. PubMed ID: 20414107
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Is the inhibition of adenosine A(2A) receptors an efficient way of Parkinson's disease treatment?].
    Ceiślak M; Komoszyński M
    Neurol Neurochir Pol; 2006; 40(3):219-26. PubMed ID: 16794962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous dopaminergic stimulation: clinical aspects and experimental bases.
    Rodriguez-Oroz MC; Marin C; de Fabregues O
    Neurologist; 2011 Nov; 17(6 Suppl 1):S30-7. PubMed ID: 22045323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New treatments for levodopa-induced motor complications.
    Rascol O; Perez-Lloret S; Ferreira JJ
    Mov Disord; 2015 Sep; 30(11):1451-60. PubMed ID: 26293004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safinamide: a new hope for Parkinson's disease?
    Teixeira FG; Gago MF; Marques P; Moreira PS; Magalhães R; Sousa N; Salgado AJ
    Drug Discov Today; 2018 Mar; 23(3):736-744. PubMed ID: 29339106
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
    Chase TN
    Neurology; 1998 May; 50(5 Suppl 5):S17-25. PubMed ID: 9591518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment.
    Chen JF
    Drug News Perspect; 2003 Nov; 16(9):597-604. PubMed ID: 14702141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of dopamine agonists in early Parkinson's disease.
    Watts RL
    Neurology; 1997 Jul; 49(1 Suppl 1):S34-48. PubMed ID: 9222273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drugs in development for Parkinson's disease.
    Johnston TH; Brotchie JM
    Curr Opin Investig Drugs; 2004 Jul; 5(7):720-6. PubMed ID: 15298067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
    Lees A
    Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical strategies to prevent and delay motor complications.
    Barone P
    Neurology; 2003 Sep; 61(6 Suppl 3):S12-6. PubMed ID: 14504375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A walk through the management of Parkinson s disease.
    Lim E
    Ann Acad Med Singap; 2005 Mar; 34(2):188-95. PubMed ID: 15827667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glutamate receptors as therapeutic targets for Parkinson's disease.
    Johnson KA; Conn PJ; Niswender CM
    CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):475-91. PubMed ID: 19702565
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical/pharmacological aspect of adenosine A2A receptor antagonist for dyskinesia.
    Kanda T; Uchida S
    Int Rev Neurobiol; 2014; 119():127-50. PubMed ID: 25175964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New directions in the drug treatment of Parkinson's disease.
    Montastruc JL; Rascol O; Senard JM
    Drugs Aging; 1996 Sep; 9(3):169-84. PubMed ID: 8877311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.